AZD9668 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchiectasis
Conditions
Bronchiectasis
Trial Timeline
Sep 1, 2008 → Apr 1, 2009
NCT ID
NCT00769119About AZD9668 + Placebo
AZD9668 + Placebo is a phase 2 stage product being developed by AstraZeneca for Bronchiectasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00769119. Target conditions include Bronchiectasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01054170 | Phase 2 | Completed |
| NCT01023516 | Phase 2 | Completed |
| NCT00769119 | Phase 2 | Completed |
| NCT00703391 | Phase 2 | Completed |
Competing Products
20 competing products in Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo to Benralizumab | AstraZeneca | Phase 3 | 77 |
| AZD5069 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin DPI (BAYQ3939) + Placebo | Novartis | Phase 3 | 77 |
| Placebo to Ciprofloxacin DPI (BAYQ3939) | Novartis | Pre-clinical | 23 |
| Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + Placebo | Novartis | Phase 3 | 77 |
| QBW251 + Placebo | Novartis | Phase 2 | 52 |
| Ciprofloxacin (Cipro, BAYQ3939) + Placebo | Novartis | Phase 2 | 52 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Aztreonam lysine | Gilead Sciences | Approved | 84 |
| AZLI | Gilead Sciences | Phase 2 | 51 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Itepekimab (SAR440340) + Placebo | Sanofi | Phase 2 | 51 |
| CSL787 + Placebo | CSL | Phase 1 | 32 |
| CSL787 + Placebo | CSL | Phase 2 | 51 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 74 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Group A + Group B | Bayer | Pre-clinical | 20 |
| BAY85-8501 + Placebo | Bayer | Phase 2 | 49 |